文献速递瓣膜病与结构性心脏病

TAVI量与结局阈值模型与结局及可及性关联

Modeling the Association of Volume vs Composite Outcome Thresholds With Outcomes and Access to Transcatheter Aortic Valve Implantation in the US.
PubMed 文献 · JAMA Cardiol · 2023-01-01

本研究基于美国STS/ACC TVT注册研究,建模比较年手术量阈值(<50或≥50例/年)与以结局为导向的中心辐射式布局对TAVI结局和地理可及性的影响。结果显示量阈值模型未显著减少不良事件(-34;95%CrI -75至8),而转向区域内最佳结局中心估计减少1261例不良结局(95%CrI 1013-1500),代价是驾车时间增加。

要点

  • 量阈值模型未显著减少30天复合不良事件,且增加驾车时间。
  • 结局阈值模型估计减少1261例不良事件,地理可及性代价相近。
  • 黑种人、西班牙裔及农村人群结果方向一致。

核心结论

  • 与现行医疗体系相比,基于结局的中心辐射式TAVI模式比模拟的量阈值更能改善全国结局,代价是驾车时间增加。
  • 为在维持地理可及性的同时提升质量,应着力减少各中心之间的结局差异。

研究设计与样本

  • 队列研究,纳入美国STS/ACC TVT注册研究中接受TAVI的患者。
  • 基线队列为2017年7月1日至2020年6月30日接受TAVI的成人,用以确定各中心年手术量与风险调整结局。
  • 在每個医院转诊区域内按年手术量(<50或≥50例/年)和STS/ACC TVT 30天TAVI复合结局分别对TAVI中心分类。
  • 对2020年7月1日至2022年3月31日接受TAVI的患者,建模假设其被治疗于最近的更高手术量中心(≥50例/年)或区域内最佳结局中心。

主要发现

  • 建模量阈值时,估计不良事件无显著减少(-34;95%CrI -75至8)。
  • 从现有中心到替代中心的中位(IQR)驾车时间为22(15-66)分钟。
  • 将照护转移至医院转诊区域内最佳结局中心,估计减少1261例不良结局(95%CrI 1013-1500)。
  • 从原中心到最佳中心的中位(IQR)驾车时间为23(15-41)分钟。
  • 在黑种人、西班牙裔及农村地区人群中观察到方向相似的发现。

临床怎么用

  • 提示仅以年手术量设阈值可能不足以改善TAVI整体结局,且会增加患者驾车负担。
  • 以区域内最佳结局中心为枢纽的布局可能更有效改善结局,但需权衡地理可及性。
  • 质量改进应聚焦于减少各中心之间的结局差异。

局限性

  • 为建模研究,假设患者转移至替代中心后的结局与替代中心基线结局一致,非实际转诊结果。
  • 结局数据基于STS/ACC TVT注册研究,可能存在登记偏倚。
  • 未报告对患者偏好、转诊流程可行性等因素的考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Professional societies and the Centers for Medicare & Medicaid Services suggest volume thresholds to ensure quality in transcatheter aortic valve implantation (TAVI). OBJECTIVE: To model the association of volume thresholds vs spoke-and-hub implementation of outcome thresholds with TAVI outcomes and geographic access. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients who enrolled in the US Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy registry. Site volume and outcomes were determined from a baseline cohort of adults undergoing TAVI between July 1, 2017, and June 30, 2020. EXPOSURES: Within each hospital referral region, TAVI sites were categorized by volume (<50 or ≥50 TAVIs per year) and separately by risk-adjusted outcome on the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy 30-day TAVI composite during the baseline period (July 2017 to June 2020). Outcomes of patients undergoing TAVIs from July 1, 2020, to March 31, 2022, were then modeled as though the patients had been treated at (1) the nearest higher volume (≥50 TAVIs per year) or (2) the best outcome site within the hospital referral region. MAIN OUTCOMES AND MEASURES: The primary outcome was the absolute difference in events between the adjusted observed and modeled 30-day composite of death, stroke, major bleeding, stage III acute kidney injury, and paravalvular leak. Data are presented as the number of events reduced under the above scenarios with 95% bayesian credible intervals (CrIs) and median (IQR) driving distance. RESULTS: The overall cohort included 166 248 patients with a mean (SD) age of 79.5 (8.6) years; 74 699 (47.3%) were female and 6657 (4.2%) were Black; 158 025 (95%) were treated in higher-volume sites (≥50 TAVIs) and 75 088 (45%) were treated in best-outcome sites. Modeling a volume threshold, there was no significant reduction in estimated adverse events (-34; 95% CrI, -75 to 8), while the median (IQR) driving time from the existing site to the alternate site was 22 (15-66) minutes. Transitioning care to the best outcome site in a hospital referral region resulted in an estimated 1261 fewer adverse outcomes (95% CrI, 1013-1500), while the median (IQR) driving time from the original site to the best site was 23 (15-41) minutes. Directionally similar findings were observed for Black individuals, Hispanic individuals, and individuals from rural areas. CONCLUSIONS AND RELEVANCE: In this study, compared with the current system of care, a modeled outcome-based spoke-and-hub paradigm of TAVI care improved national outcomes to a greater extent than a simulated volume threshold, at the cost of increased driving time. To improve quality while maintaining geographic access, efforts should focus on reducing site variation in outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nelson AJ, Wegermann ZK, Gallup D, et al. Modeling the Association of Volume vs Composite Outcome Thresholds With Outcomes and Access to Transcatheter Aortic Valve Implantation in the US. JAMA Cardiol. 2023. PMID: 37017940. doi:10.1001/jamacardio.2023.0477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。